arrow
M

Manuela Di Fusco

Pfizer
H指数:21
被引数:1,655

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States

辉瑞-生物科技COVID-19疫苗(LP.8.1-adapted,2025/2026配方)在美国18岁及以上高风险成人群体中的成本效益、公共卫生影响及预算影响

2026-05-230
OA
Reply to letter to editor “Comparative effectiveness of omicron XBB.1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis”

回复致编辑函“Omicron XBB.1.5适配COVID-19疫苗的比较效果:一项系统文献综述和网络Meta分析”

2025-12-310
OA
Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19

在患有严重新型冠状病毒肺炎高风险的美国成年人中,急性病后一年内新型冠状病毒肺炎的大量健康和经济负担

2024-02-015
OAAI